4C Biomed’s technology leverages a uniquely sensitive, immunological-based screening platform, which not only identifies novel immuno-oncology targets but also promises to accelerate the journey from discovery to clinical application.
Our unique and robust technology combines patient-derived tumor cultures or fresh tumor digests with autologous immune cells (TILs or PBMCs, respectively), providing accurate immune context. High-throughput screening methods, integrated with clinical data annotations, allows a bottom-up functional view. This workflow assists in prioritizing functionally-identified targets followed by stringent literature review, ensuring clinically relevant discoveries.
HVEM, also known as TNFRSF14 or CD270, is a unique cell surface receptor that can bind to TNF superfamily molecules as well as immunoglobulin molecules. Abnormal expression of HVEM has been reported in various cancer types, making it a promising target for immunotherapy. When HVEM binds to BTLA, it produces an inhibitory signal within the immune cell, which reduces T cell proliferation and increases cancer survival. Blocking the HVEM-BTLA interaction will alleviate the inhibitory effect on BTLA signaling. We have developed anti-4CB1, a novel fully human therapeutic anti-HVEM monoclonal antibody which is capable of blocking HVEM-BTLA interaction, inhibit downstream BTLA signaling and enhance the cytotoxicity of lymphocytes towards tumor cells. In addition, anti-4CB1 blocks the interaction of HVEM with the T-cell inhibitory receptor CD160. This unique ability to block both the HVEM-BTLA and HVEM-CD160 interactions positions anti-4CB1 as a potentially superior competitor to BTLA-targeting therapies.
Our lead has been rigorously tested In-Vitro, Ex-Vivo and In-Vivo, both as monotherapy and in combination with the gold standard, anti-PD-1 and has repeatedly achieved remarkable results. Anti-4CB1 has completed IND-enabling studies and is planned to enter clinical Phase I in 2026.
Our unique platform has a proven record of identifying IO targets: Over 20% of the immune targets we have discovered have reached the stage of clinical trials by pharma companies
Multiple patents filed, including for anti-4CB1, fully human first in class therapeutic monoclonal antibody
Awarded the IIA Grant for innovative research
Anti-4CB1 cell line and manufacturing process development completed
Our lead antibody, anti-4CB1, has promising safety and efficacy data
This website uses cookies and similar technologies such as web beacons and pixels (collectively: “cookies”). These cookies are required in order to load our website or to enable you to use certain services that our website offers. We cannot provide you with access to the website or services without these cookies, and therefore these cookies cannot be disabled. For more details, you can read our privacy policy here.